Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rifaximin for Preventing Acute Graft Versus Host Disease

NCT00967096 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT00967096
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00967096 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rifaximin for Preventing Acute Graft Versus Host Disease
Lead sponsor
Emory University
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2007
Completion date
April 30, 2009
Enrollment
20 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

bone marrow transplantation, malignancy